Results of TETimaX Trial of Langerhans Cell Histiocytosis Treatment and Perspectives on the Role of Imatinib Mesylate in the Era of MAPK Signaling

Results of TETimaX Trial of Langerhans Cell Histiocytosis Treatment and Perspectives on the Role of Imatinib Mesylate in the Era of MAPK Signaling

Langerhans cell histiocytosis (LCH) is a rare disease that has a variable clinical presentation and unpredictable behavior. Until recently, therapeutic options were limited. Insights into the role of mitogen-activated protein kinase (MAPK) signaling have allowed the increased use of targeted treatme...

Full description

Bibliographic Details
Main Authors: Liliana Montella, Margaret Ottaviano, Vittorio Riccio, Fernanda Picozzi, Gaetano Facchini, Luigi Insabato, Mario Giuliano, Giovannella Palmieri
Format: Article
Language:English
Published: MDPI AG 2021-11-01
Series:Biomedicines
Subjects:
langerhans cell histiocytosis
imatinib
B-RAF
KIT
PDGFR
Online Access:https://www.mdpi.com/2227-9059/9/12/1759

Internet

https://www.mdpi.com/2227-9059/9/12/1759

Similar Items